drugset

drugset / Trial / NCT01034267

Safety Study of F2695 SR in Major Depressive Disorder

NCT01034267 ↗

Phase 3 Completed 828 enrolled Forest Laboratories

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.

Timeline

Start: 2009-12
Primary completion: 2012-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	F2695 SR	Unknown	—	Oral

Indications